Zhilei Shan1,2,3, Taoping Sun1,2, Hao Huang1,2, Sijing Chen1,2, Liangkai Chen1,2, Cheng Luo1,2, Wei Yang1,2, Xuefeng Yang1,2, Ping Yao1,2, Jinquan Cheng4, Frank B Hu5,6, Liegang Liu7,2. 1. Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, and. 2. Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Departments of Nutrition and. 4. Shenzhen Center for Disease Control and Prevention, Shenzhen, China. 5. Departments of Nutrition and lgliu@mails.tjmu.edu.cn frank.hu@channing.harvard.edu. 6. Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; and. 7. Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, and lgliu@mails.tjmu.edu.cn frank.hu@channing.harvard.edu.
Abstract
Background: The association of trimethylamine-N-oxide (TMAO), a microbiota-dependent metabolite from dietary choline and carnitine, with type 2 diabetes was inconsistent.Objective: We evaluated the association of plasma TMAO with newly diagnosed type 2 diabetes and the potential modification of TMAO-generating enzyme flavin monooxygenase 3 (FMO3) polymorphisms.Design: This was an age- and sex-matched case-control study of 2694 participants: 1346 newly diagnosed cases of type 2 diabetes and 1348 controls. Concentrations of plasma TMAO were measured, and FMO3 E158K polymorphisms (rs2266782) were genotyped. Results: Medians (IQRs) of plasma TMAO concentration were 1.47 μmol/L (0.81-2.20 μmol/L) for controls and 1.77 μmol/L (1.09-2.80 μmol/L) for type 2 diabetes cases. From the lowest to the highest quartiles of plasma TMAO, the multivariable adjusted ORs of type 2 diabetes were 1.00 (reference), 1.38 (95% CI: 1.08, 1.77), 1.64 (95% CI: 1.28, 2.09), and 2.55 (95% CI: 1.99, 3.28) (P-trend < 0.001); each SD of ln-transformed plasma TMAO was associated with a 38% (95% CI: 26%, 51%) increment in ORs of type 2 diabetes. The FMO3 rs2266782 polymorphism was not associated with type 2 diabetes. The positive association between plasma TMAO and type 2 diabetes was consistent in each rs2266782 genotype group, and no significant interaction was observed (P = 0.093).Conclusions: Our results suggested that higher plasma TMAO was associated with increased odds of newly diagnosed type 2 diabetes and that this association was not modified by the FMO3 rs2266782 polymorphism. This study was registered at clinicaltrials.gov as NCT03130894.
Background: The association of trimethylamine-N-oxide (TMAO), a microbiota-dependent metabolite from dietary choline and carnitine, with type 2 diabetes was inconsistent.Objective: We evaluated the association of plasma TMAO with newly diagnosed type 2 diabetes and the potential modification of TMAO-generating enzyme flavin monooxygenase 3 (FMO3) polymorphisms.Design: This was an age- and sex-matched case-control study of 2694 participants: 1346 newly diagnosed cases of type 2 diabetes and 1348 controls. Concentrations of plasma TMAO were measured, and FMO3E158K polymorphisms (rs2266782) were genotyped. Results: Medians (IQRs) of plasma TMAO concentration were 1.47 μmol/L (0.81-2.20 μmol/L) for controls and 1.77 μmol/L (1.09-2.80 μmol/L) for type 2 diabetes cases. From the lowest to the highest quartiles of plasma TMAO, the multivariable adjusted ORs of type 2 diabetes were 1.00 (reference), 1.38 (95% CI: 1.08, 1.77), 1.64 (95% CI: 1.28, 2.09), and 2.55 (95% CI: 1.99, 3.28) (P-trend < 0.001); each SD of ln-transformed plasma TMAO was associated with a 38% (95% CI: 26%, 51%) increment in ORs of type 2 diabetes. The FMO3 rs2266782 polymorphism was not associated with type 2 diabetes. The positive association between plasma TMAO and type 2 diabetes was consistent in each rs2266782 genotype group, and no significant interaction was observed (P = 0.093).Conclusions: Our results suggested that higher plasma TMAO was associated with increased odds of newly diagnosed type 2 diabetes and that this association was not modified by the FMO3 rs2266782 polymorphism. This study was registered at clinicaltrials.gov as NCT03130894.
Authors: Daniel T Dibaba; Karen C Johnson; Anna M Kucharska-Newton; Katie Meyer; Steven H Zeisel; Aurelian Bidulescu Journal: Diabetes Care Date: 2020-09-08 Impact factor: 19.112
Authors: Benjamin C Fu; Meredith A J Hullar; Timothy W Randolph; Adrian A Franke; Kristine R Monroe; Iona Cheng; Lynne R Wilkens; John A Shepherd; Margaret M Madeleine; Loïc Le Marchand; Unhee Lim; Johanna W Lampe Journal: Am J Clin Nutr Date: 2020-06-01 Impact factor: 7.045
Authors: Christopher Papandreou; Mònica Bulló; Yan Zheng; Miguel Ruiz-Canela; Edward Yu; Marta Guasch-Ferré; Estefanía Toledo; Clary Clish; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Fernando Arós; Miquel Fiol; José Lapetra; Lluís Serra-Majem; Enrique Gómez-Gracia; Liming Liang; Georgios A Fragkiadakis; Cristina Razquin; Frank B Hu; Jordi Salas-Salvadó Journal: Am J Clin Nutr Date: 2018-07-01 Impact factor: 7.045